PO.CL12.01 · 临床研究

使用皮秒红外激光质谱统一平台在10秒内对中枢神经系统癌症进行形态计量学与分子学整合分类

Integrated morphometric and molecular classification of central nervous system cancers in 10 seconds using a unified platform with picosecond infrared laser mass spectrometry

编号 3883 展板 16 时间 4/20 02:00–05:00 区域 Section 46 主讲 Arash Zarrine-Afsar, D Phil
分会场 Molecular Classification and Tumor Biology in Cancer
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Alexa Nina Fiorante1, Michael Woolman1, David Munoz2, Farshad Nassiri3, Gelareh Zadeh4, Sunit Das2, Howard Ginsberg2, Arash Zarrine-Afsar3

1University of Toronto, Toronto, ON, Canada,2Unity Health, St. Michael's Hospital, Toronto, ON, Canada,3UHN Princess Margaret Cancer Centre, Toronto, ON, Canada,4UHN Princess Margaret Cancer Centre, Toronto, ON, Canada, Toronto, ON, Canada

摘要 Abstract

中文摘要
世界卫生组织(WHO)现在提倡在中枢神经系统(CNS)癌症的诊断中采用整合方法。然而,所提出的WHO工作流程较为复杂,严重依赖多种仪器——如基因测序仪和免疫组化扫描仪——且周转时间不一,往往较长。 利用脂质代谢与癌症之间的联系,我们证明皮秒红外激光质谱(PIRL-MS)能够在仅10秒内分析组织脂质组,对CNS肿瘤类型预测达到超过80%的敏感性和特异性。这一方法在一个大型队列中得到验证,包括150例儿童(3种形态计量学上不同的类型,7个分子类别)和1,142例成人(24种形态计量学类型,8个分子类别)脑肿瘤类型。虽然初步结果提供了较强的分类能力,但尚未达到稳健的诊断标准,目前正在纳入机器学习,已在部分病例中将敏感性和特异性提高到94%以上。 PIRL-MS基于下游表型组(脂质组)变化,为形态学和分子学上不同的肿瘤(亚)型(如IDH突变状态、髓母细胞瘤亚组)提供10秒诊断的能力,为统一诊断平台开辟了清晰的路径。该方法可在单一仪器上于数秒内整合形态计量学和分子学诊断,极大减少了对组织操作和冗长制备步骤的需求,这是当前方法无法企及的成就。
查看英文原文 English abstract
The World Health Organization (WHO) now advocates for an integrated approach in the diagnosis of Central Nervous System (CNS) cancers. However, the proposed WHO workflow is complex, relying heavily on multiple instruments-like genetic sequencers and immunohistochemistry scanners-with variable, often lengthy, turnaround times. Leveraging the link between lipid metabolism and cancer, we demonstrate that Picosecond InfraRed Laser Mass Spectrometry (PIRL-MS) can profile the tissue lipidome in just 10 seconds, achieving over 80% sensitivity and specificity for CNS tumor type prediction. This was validated across a large cohort of 150 pediatric (3 morphometrically distinct types, 7 molecular classes) and 1,142 adult (24 morphometric, 8 molecular classes) brain tumour types. While initial results provided strong classification, falling short of robust diagnostic criteria, the ongoing incorporation of machine learning has increased sensitivity and specificity to over 94% in select cases. The capabilities of PIRL-MS to deliver a 10-second diagnosis-based on downstream phenomic (lipidomic) changes-for both morphologically and molecularly distinct tumor (sub)types (e.g., IDH mutation status, medulloblastoma subgroups) offers a clear path toward a unified diagnostic platform. This approach can integrate morphometric and molecular diagnoses on a single instrument in seconds, drastically reducing the need for tissue manipulation and lengthy preparation steps, a feat unmatched by current methods.
利益披露 Disclosure
M. Woolman, Point Surgical Inc. Independent Contractor, Other Securities, Patent. D. Munoz, None.. F. Nassiri, None.. G. Zadeh, None. S. Das, Congress of Neurological Surgeons Travel, Other, Speaker. American Association of Neurosurgery Travel, Other, Speaker. Provincial Lead for CNS Oncology at Ontario Health (Cancer Care Ontario) Independent Contractor, Other, Receives Stipend. VPIX Medical. ). Synaptive ). Cure51 ). Oxford University Press Other, Royalties. Subcortical Surgery Group Advisory board. H. Ginsberg, Point Surgical Inc. g., Board of Directors, non-salaried role), Other Securities, Patent. A. Zarrine-Afsar, Point Surgical Inc. g., Board of Directors, non-salaried role), Independent Contractor, Other Securities, Patent. Waters Corporation Travel. Japan Society for Medical Mass Spectrometry Travel. Brazilian Society for Mass Spectrometry Travel.

← 返回 AACR 2026 检索